About: Computational Design of Peptides to Block Binding of the SARS-CoV-2 Spike Protein to Human ACE2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Computational Design of Peptides to Block Binding of the SARS-CoV-2 Spike Protein to Human ACE2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Computational Design of Peptides to Block Binding of the SARS-CoV-2 Spike Protein to Human ACE2
Creator	Zhang, Yang Huang, Xiaoqiang Pearce, Robin
Source	BioRxiv
abstract	The outbreak of COVID-19 has now become a global pandemic and it continues to spread rapidly worldwide, severely threatening lives and economic stability. Making the problem worse, there is no specific antiviral drug that can be used to treat COVID-19 to date. SARS-CoV-2 initiates its entry into human cells by binding to angiotensin-converting enzyme 2 (hACE2) via the receptor binding domain (RBD) of its spike protein. Therefore, molecules that can block SARS-CoV-2 from binding to hACE2 may potentially prevent the virus from entering human cells and serve as an effective antiviral drug. Based on this idea, we designed a series of peptides that can strongly bind to SARS-CoV-2 RBD in computational experiments. Specifically, we first constructed a 31-mer peptidic scaffold by linking two fragments grafted from hACE2 (a.a. 22-44 and 351-357) with a linker glycine, and then redesigned the peptide sequence to enhance its binding affinity to SARS-CoV-2 RBD. Compared with several computational studies that failed to identify that SARS-CoV-2 shows higher binding affinity for hACE2 than SARS-CoV, our protein design scoring function, EvoEF2, makes a correct identification, which is consistent with the recently reported experimental data, implying its high accuracy. The top designed peptide binders exhibited much stronger binding potency to hACE2 than the wild-type (−53.35 vs. −46.46 EvoEF2 energy unit for design and wild-type, respectively). The extensive and detailed computational analyses support the high reasonability of the designed binders, which not only recapitulated the critical native binding interactions but also introduced new favorable interactions to enhance binding. Due to the urgent situation created by COVID-19, we share these computational data to the community, which should be helpful to develop potential antiviral peptide drugs to combat this pandemic.
has issue date	2020-03-31(xsd:dateTime)
bibo:doi	10.1101/2020.03.28.013607
has license	biorxiv
sha1sum (hex)	8e8e21faa69a8a8919a3f07615ffc08ea1627f8d
schema:url	https://doi.org/10.1101/2020.03.28.013607
resource representing a document's title	Computational Design of Peptides to Block Binding of the SARS-CoV-2 Spike Protein to Human ACE2
schema:publication	bioRxiv
resource representing a document's body	covid:8e8e21faa69a8a8919a3f07615ffc08ea1627f8d#body_text
is schema:about of	named entity 'extensive' named entity 'a.a.' named entity 'protein design' named entity 'initiates' named entity 'linking' named entity 'Spike' named entity 'Design' named entity 'CONSISTENT WITH' named entity 'NEW' named entity 'HACE2' named entity 'IDEA' named entity 'SPIKE PROTEIN' named entity 'PROBLEM' named entity 'ECONOMIC' named entity 'GLYCINE' named entity 'ANGIOTENSIN-CONVERTING ENZYME 2' named entity 'INTRODUCED' named entity 'CONSTRUCTED' named entity 'HUMAN CELLS' named entity 'NATIVE' named entity 'STUDIES' named entity 'SPECIFIC' named entity 'LINKING' named entity 'SHARE' named entity 'WILD-TYPE' named entity 'OUTBREAK' named entity 'ACCURACY' named entity 'CORRECT' named entity 'problem' named entity 'angiotensin-converting enzyme 2' named entity 'bind' named entity 'computational' named entity 'fragments' named entity 'SARS-CoV-2' named entity 'data' named entity 'prevent' named entity 'computational' named entity 'higher' named entity 'Due' named entity 'binders' named entity 'binding' named entity 'molecules' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'receptor binding domain' named entity 'spike protein' named entity 'COVID-19' named entity 'protein design' named entity 'potency' named entity 'peptide' named entity 'peptide' named entity 'binding affinity' named entity 'SARS-CoV-2' named entity 'hydrogen bonds' named entity 'COVID' named entity 'peptide' named entity 'secondary structure' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'peptide' named entity 'wildtype' named entity 'SARS-CoV-2' named entity 'crystal structure' named entity 'wild-type' named entity 'hACE2' named entity 'SARS-CoV-2' named entity 'peptide' named entity 'coronavirus disease 2019' named entity 'evolution' named entity 'PPIs' named entity 'COVID-19 pandemic' named entity 'EEU' named entity 'hydrogen bonds' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'virus' named entity 'peptide' named entity 'binding affinity' named entity 'protein' named entity 'SARS-CoV-2' named entity 'H34' named entity 'peptidic' named entity 'wild-type'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software